Bionano Genomics, Inc (BNGO) 10K Annual Reports & 10Q SEC Filings

SAN DIEGO, March 5, 2024 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2023 and revenue outlook for 2024.

“2023 was a year in which we made tremendous progress toward our mission of transforming the way the world sees the genome. The progress is evidence that our ELEVATE strategy is working,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano. “Revenue growth continued with growth of the OGM installed base and consumables units sales. We had a number of significant product launches during 2023, which we believe will make OGM easier to implement and use and make it possible to run substantially more samples. Innovations such as the Stratys™ system for high throughput mapping, and VIA™ software for streamlined visualization, interpretation and reporting of genome analysis results have been enthusiastically received and we expect them to be drivers of revenue growth. We also saw independent confirmation of the utility of our solutions, including the organization of consortia across the world who are driving OGM adoption and implementation. We believe the execution of ELEVATE with the progress of OGM in 2023, and our focus on reducing cash burn, including through new cost savings initiatives introduced today, we are well-positioned us for success in 2024.”

Recent Highlights

•Announced the commercial release of the Stratys™ system, the Company’s system for high throughput OGM, and the completion of the Stratys early access program, which includes 11 systems at 10 customer sites across the globe.

•Published the first framework paper for the uniform clinical adoption and implementation of the OGM workflow for hematological malignancy applications, authored by an international consortium of 18 researchers.

•Published interim readout from second phase of prenatal validation study, which evaluated 342 unique cases for prenatal genetic disease using OGM; results showed OGM to have 100% concordance with traditional cytogenetic methods, with sensitivity of 99.2%, specificity of 100%, and overall accuracy of 99.6%.

•Published peer-reviewed publication for the second phase of postnatal validation study, which evaluated 627 constitutional postnatal samples using OGM; results showed that 99.5% of samples were fully concordant with standard of care (SOC) methods; when compared to the rate of finding pathogenic or likely pathogenic variants with SOC methods, OGM increased the rate by a factor of 6% to as much as 50% depending on the sample population.

•Held 2024 Symposium, which featured a record 32 oral presentations and 69 scientific posters from genomic scientists at leading global institutions on the use of

The following information was filed by Bionano Genomics, Inc (BNGO) on Tuesday, March 5, 2024 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1411690/000141169024000013/bngo-20231231.htm

View differences made from one year to another to evaluate Bionano Genomics, Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Bionano Genomics, Inc.

Continue

Assess how Bionano Genomics, Inc's management team is paid from their Annual Proxy

Bionano Genomics, Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Bionano Genomics, Inc provided additional information to their SEC Filing as exhibits

Exhibit 4.1: Instruments Defining The Rights Of Security Holders, Including Indentures

Exhibit 4.5: Instruments Defining The Rights Of Security Holders, Including Indentures

Exhibit 22.1: Published Report Regarding Matters Submitted To Vote Of Security Holders

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Exhibit 97.1: Ex-97.1

Ticker: BNGO
CIK: 1411690
Form Type: 10-K Annual Report
Accession Number: 0001411690-24-000013
Submitted to the SEC: Tue Mar 05 2024 5:26:17 PM EST
Accepted by the SEC: Tue Mar 05 2024
Period: Sunday, December 31, 2023
Industry: Laboratory Analytical Instruments

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/bngo/0001411690-24-000013.htm

Bionano Genomics, Inc. (BNGO) SEC Filing 10-K Annual Report for the fiscal year ending Sunday, December 31, 2023

SEC Filings

BNGO Valuations

BNGO Annual Reports

BNGO Quarterly Reports

BNGO Corporate News

BNGO Registration of Securities